Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
First Bancorp
FBNC
$2.75B
| $11.8M | 0.02% |
377,033
-135,567
| -26% | -$4.01M |
|
1177
Core Laboratories
CLB
$583M
| $11.8M | 0.02% |
116,200
-55,900
| -32% | -$6.03M |
|
|
AE
1178
DELISTED
Adams Resources & Energy Inc
AE
| $11.7M | 0.02% |
285,900
+900
| +0.3% | +$36.1K |
|
|
ANCX
1179
DELISTED
Access National Corp
ANCX
| $11.7M | 0.02% |
442,305
+165,905
| +60% | +$4.67M |
|
1180
First Commonwealth Financial
FCF
$2.19B
| $11.7M | 0.01% |
923,800
-148,100
| -14% | -$1.89M |
|
1181
Sanmina
SANM
$11.3B
| $11.7M | 0.01% |
306,933
+102,200
| +50% | +$3.88M |
|
1182
iRhythm Holdings
IRTC
$4.13B
| $11.7M | 0.01% |
274,800
+187,600
| +215% | +$6.83M |
|
|
PE
1183
DELISTED
PARSLEY ENERGY INC
PE
| $11.7M | 0.01% |
+420,700
| New | +$12.5M |
|
|
IMPV
1184
DELISTED
Imperva, Inc.
IMPV
| $11.7M | 0.01% |
+243,919
| New | +$11.4M |
|
|
HMSY
1185
DELISTED
HMS Holdings Corp.
HMSY
| $11.7M | 0.01% |
630,312
-4,200
| -0.7% | -$80.8K |
|
1186
Apple Hospitality REIT
APLE
$3.79B
| $11.7M | 0.01% |
623,200
-67,035
| -10% | -$1.27M |
|
1187
Erie Indemnity
ERIE
$13.4B
| $11.6M | 0.01% |
93,000
+6,729
| +8% | +$812K |
|
|
GXP
1188
DELISTED
Great Plains Energy Incorporated
GXP
| $11.6M | 0.01% |
396,215
-478,700
| -55% | -$13.9M |
|
1189
Entravision Communication
EVC
$822M
| $11.5M | 0.01% |
1,746,000
-219,552
| -11% | -$1.33M |
|
1190
BioMarin Pharmaceuticals
BMRN
$13B
| $11.5M | 0.01% |
+126,871
| New | +$11.5M |
|
|
PSTB
1191
DELISTED
Park Sterling Corp.
PSTB
| $11.5M | 0.01% |
967,973
+185,850
| +24% | +$2.21M |
|
|
BELFB
1192
Bel Fuse Inc Class B
BELFB
$4.24B
| $11.5M | 0.01% |
464,417
-15,300
| -3% | -$368K |
|
1193
Cohu
COHU
$2.83B
| $11.5M | 0.01% |
728,254
+43,795
| +6% | +$802K |
|
1194
Restaurant Brands International
QSR
$27B
| $11.5M | 0.01% |
183,200
+97,013
| +113% | +$5.72M |
|
|
ADSW
1195
DELISTED
Advanced Disposal Services Inc
ADSW
| $11.4M | 0.01% |
503,600
+344,800
| +217% | +$7.96M |
|
1196
Vermilion Energy
VET
$1.74B
| $11.4M | 0.01% |
360,288
+244,500
| +211% | +$8.4M |
|
|
FFNW
1197
DELISTED
First Financial Northwest, Inc
FFNW
| $11.4M | 0.01% |
707,700
-23,400
| -3% | -$379K |
|
|
AIQ
1198
DELISTED
Alliance Healthcare Services
AIQ
| $11.4M | 0.01% |
857,760
+62,300
| +8% | +$801K |
|
|
CIM
1199
Chimera Investment
CIM
$1B
| $11.4M | 0.01% |
203,887
+109,000
| +115% | +$6.31M |
|
|
PMD
1200
DELISTED
Psychemedics Corporation
PMD
| $11.4M | 0.01% |
456,500
-10,900
| -2% | -$229K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.